Goodwin
Robert Crawford
- Deals
- 2
- Latest
- Jul 2026
- Most deals in
- Pharma
Firm
- Goodwin Law firm · 2026 · 2 deals
Often works with
- Jacqueline Mercier 1 deal together
- Catherine Magazu 1 deal together
- Jennifer Ford 1 deal together
- Ana Carolina Zattar 1 deal together
- Kris Brown 1 deal together
- Evan De Ycaza 1 deal together
- Huiya Wu 1 deal together
- Dan Karelitz 1 deal together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Jul 2026 | Neurimmune's royalty interest in AstraZeneca's cliramitug | Neurimmune | Royalty Pharma | Asset sale | Legal adviser to Royalty Pharma (acquirer) | Announced | 250.0 | Pharma+1 | Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug |
| Apr 2026 | Worldwide rights to Kenalog | Bristol-Myers Squibb | Subsidiary of Piramal Pharma | Asset sale | Legal adviser to subsidiary of Piramal Pharma (acquirer) | Announced | 35.0 | Pharma | Subsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog |
Deals where Robert Crawford is named on the firm's deal team, by the firm or the press.